Skip to main content
VREOF
OTC Life Sciences

Vireo Growth Reports 333% Q1 Revenue Growth, Details M&A Impact

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
9
Price
$0.4
Mkt Cap
$468.332M
52W Low
$0.315
52W High
$0.8
Market data snapshot near publication time

summarizeSummary

Vireo Growth Inc. reported exceptional Q1 2026 financial results with revenue up 333.5% year-over-year, driven by successful integration of recent major acquisitions, solidifying its position as a top cannabis company.


check_boxKey Events

  • Exceptional Q1 2026 Financial Growth

    GAAP revenue surged 333.5% year-over-year to $106.2 million, with Adjusted EBITDA increasing 395.5% to $32.7 million, driven by recent acquisitions.

  • Strategic M&A Integration and Expansion

    The company completed the Schwazze, Eaze, and Hawthorne acquisitions, significantly expanding its market presence and positioning it as the 4th largest cannabis company on a pro forma basis.

  • Updated Share Count Post-Acquisitions

    Subordinate voting shares outstanding increased to 1,568,115,539 as of May 12, 2026, reflecting share issuances for recent mergers, which is relevant to the pending reverse stock split.

  • Healthy Cash Position

    Vireo Growth Inc. reported $137.8 million in cash on hand as of March 31, 2026, supporting its continued acquisitive strategy.


auto_awesomeAnalysis

This 8-K is highly important as it details Vireo Growth Inc.'s Q1 2026 financial performance, showcasing massive year-over-year growth in revenue and Adjusted EBITDA, primarily due to its aggressive and successful M&A strategy. The company is rapidly consolidating the cannabis market, moving to the 4th largest player on a pro forma basis. The updated share count, a direct result of these acquisitions, provides critical context for investors, especially given the previously announced proposed reverse stock split. The healthy cash balance indicates continued capacity for strategic growth.

At the time of this filing, VREOF was trading at $0.40 on OTC in the Life Sciences sector, with a market capitalization of approximately $468.3M. The 52-week trading range was $0.31 to $0.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed VREOF - Latest Insights

VREOF
May 12, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
VREOF
May 05, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
VREOF
Apr 16, 2026, 4:07 PM EDT
Filing Type: DEFA14A
Importance Score:
8
VREOF
Apr 16, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
9
VREOF
Apr 14, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
VREOF
Apr 06, 2026, 4:20 PM EDT
Filing Type: PRE 14A
Importance Score:
9
VREOF
Apr 06, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
VREOF
Mar 25, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
VREOF
Mar 17, 2026, 4:45 PM EDT
Filing Type: 10-K
Importance Score:
9
VREOF
Mar 17, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8